InsightsPremium
Sigilon Therapeutics logo

Sigilon Therapeutics

2 Followers

About

Sigilon Therapeutics’ mission is to create immune-protected, engineered human cells that restore normal physiology in a wide range of diseases without generating fibrosis or immune rejection, liberating patients from challenges associated with serious chronic diseases.

Deya Corzo
Deya Corzo
Chief Medical Officer
Matthew Kowalsky
Matthew Kowalsky
Chief Legal Officer
Philip Ashton-Rickardt
Philip Ashton-Rickardt
Chief Scientific Officer
Martha Rook
Martha Rook
Chief Technical Operations Officer
Vanya Sagar
Vanya Sagar
CHRO
Josias Pontes
Josias Pontes
VP, Head of Finance
Susan Drapeau
Susan Drapeau
VP, Head of Device and Delivery Engineering
Hozefa Bandukwala
Hozefa Bandukwala
VP, Platform Innovation
Robert Windsor Jr.
Robert Windsor Jr.
VP, Head of Investor Relations
Jiang Wu
Jiang Wu
VP, Head of Bioanalytical & CMC Analytical Development
Bernd Kullmann
Bernd Kullmann
VP, Head of Manufacturing & Supply Chain

No teams yet!

No jobs yet!

No wires yet!

By clicking "Continue" or continuing to use our site, you acknowledge that you accept our Privacy Policy and Terms of Use. We also use cookies to provide you with the best possible experience on our website.